Loading...

Brilliant Violet 510™ anti-mouse/human CD11b Antibody

Pricing & Availability
Clone
M1/70 (See other available formats)
Regulatory Status
RUO
Other Names
αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M170_BV510_CD11b_Antibody_FC_082512
C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 510™. Data shown was gated on the myeloid cell population.
  • M170_BV510_CD11b_Antibody_FC_082512
    C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 510™. Data shown was gated on the myeloid cell population.
  • M170_BV510_CD11b_Antibody_ICC_121319
    C57 mouse bone marrow cells were fixed with 2% paraformaldehyde (PFA), and then stained with 10 µg/ml of CD11b (clone M1/70) Brilliant Violet 510™ (red) and 10 µg/ml of CD45 (clone 30-F11) Alexa Fluor® 647 (blue) for 30 minutes at room temperature. The image was captured by 60X objective.
Compare all formats See Brilliant Violet 510™ spectral data See high resolution IF data...
Cat # Size Price Quantity Check Availability Save
101245 125 µL 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101263 50 µg 206€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Rabbit
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µL size, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤ 0.4 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  36. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Peterson T, et al. 2016. Proc Natl Acad Sci U S A. 113: 4470-4475. PubMed
  2. Ender F, et al. 2017. PLoS One. 12(2):e0172446. PubMed
  3. Ramakrishna C, et al. 2019. Nat Commun. 10:2153. PubMed
  4. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  5. Fang C, et al. 2022. J Pathol. 256:310. PubMed
  6. Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed
  7. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  8. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  9. Campisi L, et al. 2022. Nature. 606:945. PubMed
  10. Jiang H, et al. 2022. Oxid Med Cell Longev. 2022:5064494. PubMed
  11. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  12. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  13. Montilla A, et al. 2023. Cell Death Dis. 14:16. PubMed
  14. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  15. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  16. Jameson VJ, et al. 2022. Cytometry A. 101:922. PubMed
  17. Pérez-Torrado V, et al. 2022. Bio Protoc. 12:. PubMed
  18. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  19. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  20. Daum P, et al. 2023. Front Immunol. 13:991347. PubMed
  21. Solier S, et al. 2023. Int J Mol Sci. 24:. PubMed
  22. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  23. Xu H, et al. 2023. Elife. 12:. PubMed
  24. Read KA, et al. 2023. Nat Commun. 14:1652. PubMed
  25. Zhang Y, et al. 2023. J Immunol Res. 2023:5867047. PubMed
  26. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  27. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  28. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  29. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  30. Kloepper J, et al. 2016. Proc Natl Acad Sci U S A. 113: 4476-4481. PubMed
  31. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  32. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  33. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  34. Shmuel-Galia L, et al. 2021. Immunity. 54(6):1137-1153.e8. PubMed
  35. Kim YS, et al. 2021. Cell Death Dis. 12:307. PubMed
  36. Wong J, et al. 2020. PLoS One. 15:e0233794. PubMed
  37. Park JH, et al. 2022. STAR Protoc. 3:101607. PubMed
  38. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  39. Vicetti Miguel R, et al. 2016. PLoS One. 11: 0162445. PubMed
  40. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  41. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  42. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  43. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  44. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  45. Mitsune A, et al. 2021. Respir Res. 22:232. PubMed
  46. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  47. El Amki M, et al. 2020. Cell Rep. 33:108260. PubMed
  48. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  49. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
  50. Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed
  51. Meixiong J et al. 2019. Immunity. 50(5):1163-1171 . PubMed
  52. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  53. LaMothe RA et al. 2018. Front Immunol. 0.570138889 . PubMed
  54. Akagi T, et al. 2022. Front Immunol. 13:926175. PubMed
  55. Burns JC, et al. 2021. Bio Protoc. 11:e4091. PubMed
  56. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
  57. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  58. Affo S, et al. 2021. Cancer Cell. 39(6):866-882.e11. PubMed
  59. Green DP, et al. 2019. Neuron. 101:412. PubMed
  60. Schaffert A, et al. 2020. Front Immunol. 10:3024. PubMed
  61. Woods T, et al. 2016. J Virol. 90: 2783 - 2793. PubMed
  62. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  63. Zheng J, et al. 2020. bioRxiv. . PubMed
  64. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  65. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  66. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  67. Christ A, et al. 2018. Cell. 172:162. PubMed
  68. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  69. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  70. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  71. Ercoli G, et al. 2022. Clin Transl Immunology. 11:e1366. PubMed
  72. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  73. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  74. Burns JC, et al. 2020. eLife. 9:00. PubMed
  75. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  76. Zheng J, et al. 2020. Nature. . PubMed
  77. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  78. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  79. Smith CA, et al. 2019. JCI Insight. 4. PubMed
  80. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  81. Luo J et al. 2018. Immunity. 49(1):107-119 . PubMed
  82. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  83. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  84. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  85. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  86. Ahn D, et al. 2021. Cell Reports. 35(9):109196. PubMed
  87. Gentek R, et al. 2018. Immunity. 48:1160. PubMed
  88. Hoffmann FM, et al. 2018. Front Immunol. 9:1046. PubMed
  89. Platten M, et al. 2021. Nature. 592:463. PubMed
  90. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  91. Ma Y, et al. 2022. Front Immunol. 13:816952. PubMed
  92. Xu G, et al. 2022. Front Pharmacol. 13:896601. PubMed
  93. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  94. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  95. Kerkhofs D, et al. 2020. Theranostics. 7.022222222. PubMed
  96. McDonald LT, et al. 2017. PLoS One. 12:e0180724. PubMed
  97. Briukhovetska D, et al. 2020. Frontiers in Immunology. 1.428472222. PubMed
  98. Jeljeli M, et al. 2021. Front Immunol. 12:670776. PubMed
  99. Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed
  100. Wei Y, et al. 2021. Endocrinology. 162(8):. PubMed
  101. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  102. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  103. Eremenko E, et al. 2019. EBioMedicine. 43:424. PubMed
  104. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  105. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  106. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  107. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  108. Cardoso M, et al. 2015. Infect Immun . 83: 3534-3544. PubMed
  109. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  110. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
  111. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  112. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  113. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  114. Samuelson DR, et al. 2021. Commun Biol. 4:997. PubMed
RRID
AB_2561390 (BioLegend Cat. No. 101245)
AB_2561390 (BioLegend Cat. No. 101263)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
UniProt
View information about CD11b on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD11b Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse/human CD11b M1/70 FC
Biotin anti-mouse/human CD11b M1/70 FC
FITC anti-mouse/human CD11b M1/70 FC
PE anti-mouse/human CD11b M1/70 FC,IHC
PE/Cyanine5 anti-mouse/human CD11b M1/70 FC
Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,IHC-F,ICC
PE/Cyanine7 anti-mouse/human CD11b M1/70 FC
Alexa Fluor® 488 anti-mouse/human CD11b M1/70 FC,IHC-F,3D IHC,SB
Alexa Fluor® 647 anti-mouse/human CD11b M1/70 FC,3D IHC,SB
Alexa Fluor® 700 anti-mouse/human CD11b M1/70 FC
Pacific Blue™ anti-mouse/human CD11b M1/70 FC
APC/Cyanine7 anti-mouse/human CD11b M1/70 FC
PerCP/Cyanine5.5 anti-mouse/human CD11b M1/70 FC
PerCP anti-mouse/human CD11b M1/70 FC
Brilliant Violet 421™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 570™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 605™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 650™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 711™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 785™ anti-mouse/human CD11b M1/70 FC
Brilliant Violet 510™ anti-mouse/human CD11b M1/70 FC,ICC
Ultra-LEAF™ Purified anti-mouse/human CD11b M1/70 FC,CyTOF®,IP,Block,Depletion,IHC-F,ICC
Purified anti-mouse/human CD11b (Maxpar® Ready) M1/70 FC,CyTOF®
Alexa Fluor® 594 anti-mouse/human CD11b M1/70 IHC-F,FC
PE/Dazzle™ 594 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 750 anti-mouse/human CD11b M1/70 FC
TotalSeq™-A0014 anti-mouse/human CD11b M1/70 PG
Brilliant Violet 750™ anti-mouse/human CD11b M1/70 FC
TotalSeq™-B0014 anti-mouse/human CD11b M1/70 PG
TotalSeq™-C0014 anti-mouse/human CD11b M1/70 PG
Spark NIR™ 685 anti-mouse/human CD11b M1/70 FC
PE/Fire™ 640 anti-mouse/human CD11b M1/70 FC
Spark YG™ 593 anti-mouse/human CD11b M1/70 FC
Spark YG™ 570 anti-mouse/human CD11b M1/70 IHC-F
PE/Fire™ 810 anti-mouse/human CD11b M1/70 FC
APC/Fire™ 810 anti-mouse/human CD11b Antibody M1/70 FC
Spark Blue™ 550 anti-mouse/human CD11b M1/70 FC
Spark UV™ 387 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 806 anti-mouse/human CD11b M1/70 FC
PerCP/Fire™ 780 anti-mouse/human CD11b M1/70 FC
Spark Blue™ 574 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
KIRAVIA Blue 520™ anti-mouse/human CD11b M1/70 FC
PE/Fire™ 744 anti-mouse/human CD11b M1/70 FC
Spark PLUS UV395™ anti-mouse/human CD11b M1/70 FC
Spark Red™ 718 anti-mouse/human CD11b (Flexi-Fluor™) M1/70 FC
Go To Top Version: 3    Revision Date: 07/08/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account